Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508018-41-00

Acronym

SRA-MMB-4365/219627

Enrollment

185

Registered

2024-07-02

Start date

2018-07-27

Completion date

Unknown

Last updated

2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF), Primary Myelofibrosis (PMF)

Brief summary

Safety: Incidence, severity, seriousness, and causal relationship of AEs, as defined by CTCAE Version 4.03

Detailed description

Efficacy: overall survival (OS) and leukemia-free survival (LFS)

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety: Incidence, severity, seriousness, and causal relationship of AEs, as defined by CTCAE Version 4.03	—

Secondary

Measure	Time frame
Efficacy: overall survival (OS) and leukemia-free survival (LFS)	—

Countries

Belgium, Bulgaria, Denmark, France, Germany, Hungary, Italy, Poland, Romania, Spain

Outcome results